Leung Kam
National Center for Biotechnology Information, NLM, NIH, Bethesda, MD
Malignant melanoma is the most deadly form of skin cancer (1). Early and accurate diagnosis is necessary for surgery and successful treatment (2). The melanocortin (MC) system is a neuropeptide network of the skin, and it is involved in pigmentation regulation, cortisol production, and many other physiological processes (3). Most cutaneous cell types express MC receptors, pro-opiomelanocortin (POMC), and prohormone convertases, and they also release MCs. Melanotropin-stimulating hormones (α-, β-, and γ-MSH) are derived from POMC by the proteolytic action of prohormone convertases. There are five MC receptors (MC1R to MC5R), which belong to the G-protein−coupled receptor superfamily. However, these receptors have been found to be overexpressed in melanoma cells (4, 5). α-MSH (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH), produced by the brain and pituitary gland, is a tridecapeptide (13 amino acids) and is the most potent melanotropic peptide (6) in the regulation of skin pigmentation the MC1R. Although positron emission tomography (PET) imaging with [F]fluoro-2-deoxy-2-d-glucose ([F]FDG) is effective in the detection of melanoma, it is not melanoma-specific and some melanoma cells do not take up [F]FDG (7, 8). Radiolabeled α-MSH peptide analogs have been shown to specifically bind to MC1R that is overexpressed on human and mouse melanoma cells (4, 5, 7, 9, 10). 1,4,7,10-Tetraazacyclododecane-,,,-tetraacetic acid (DOTA) has been successfully coupled to the α-MSH peptide analogs for radiolabeling with a variety of radionuclides (7). In- and Tc-DOTA-Re(Arg)CCMSH showed favorable tumor imaging properties in mice bearing murine melanoma (11). To improve the tumor/kidney uptake ratio and stability, a rhenium-cyclized α-MSH analog, Re-[Cys,D-Phe,Arg]α-MSH (Re-CCMSH(Arg)), was conjugated with DOTA. DOTA-Re-CCMSH(Arg) was radiolabeled with Cu as a potential molecular imaging agent to target melanoma (12). Cu is a positron emitter with a physical half-life of 12.7 h and is suitable for PET imaging.
恶性黑色素瘤是皮肤癌中最致命的一种(1)。早期准确诊断对于手术和成功治疗至关重要(2)。黑皮质素(MC)系统是皮肤的一种神经肽网络,参与色素沉着调节、皮质醇生成及许多其他生理过程(3)。大多数皮肤细胞类型表达MC受体、阿片促黑皮质素原(POMC)和激素原转化酶,并且它们也释放MC。促黑素激素(α-、β-和γ-MSH)是通过激素原转化酶的蛋白水解作用从POMC衍生而来。有五种MC受体(MC1R至MC5R),它们属于G蛋白偶联受体超家族。然而,已发现这些受体在黑色素瘤细胞中过表达(4,5)。由脑和垂体产生的α-MSH(Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH)是一种十三肽(13个氨基酸),是调节皮肤色素沉着(MC1R)中最有效的促黑素肽(6)。尽管用[F]氟-2-脱氧-2-D-葡萄糖([F]FDG)进行正电子发射断层扫描(PET)成像在检测黑色素瘤方面有效,但它并非黑色素瘤特异性的,并且一些黑色素瘤细胞不摄取[F]FDG(7,8)。放射性标记的α-MSH肽类似物已被证明能特异性结合在人和小鼠黑色素瘤细胞上过表达的MC1R(4,5,7,9,10)。1,4,7,10-四氮杂环十二烷-N,N',N'',N'''-四乙酸(DOTA)已成功与α-MSH肽类似物偶联,用于用多种放射性核素进行放射性标记(7)。铟和锝标记的DOTA-Re(Arg)CCMSH在携带鼠黑色素瘤的小鼠中显示出良好的肿瘤成像特性(11)。为了提高肿瘤/肾脏摄取率和稳定性,一种铼环化的α-MSH类似物Re-[Cys,D-Phe,Arg]α-MSH(Re-CCMSH(Arg))与DOTA偶联。DOTA-Re-CCMSH(Arg)用铜进行放射性标记,作为一种潜在的靶向黑色素瘤的分子成像剂(12)。铜是一种正电子发射体,物理半衰期为12.7小时,适用于PET成像。